Table 3.

Analysis of plasma samples of follow-up cases

Patient codeTumor samplePlasma samples collected before commencement of treatmentPlasma samples collected during or after treatment*Time after TKI treatment commenced (wk)Response to TKI treatment
MutationMutant percentageMutationMutant concentration (copies/mL)MutationMutant concentration (copies/mL)
(A) Cases without pretreatment plasma samples
    Case 1Del1947NAND30SD
    Case 2Del1953NAND32PR
    Case 7L858R33NAND54PR
    Case 9Del199.8NAND20PR
Del1937026*SD*
    Case 12L858R44NAND4PR
(B) Cases with pretreatment plasma samples
Case 8L858R40L858R3.2ND60PR
Case 15L858R19L858R55L858R5526PD
Case 26L858R62L858R8,300L858R10014PR
Case 38L858R39L858R34,000L858R784CR
Case 39L858R26L858R9.7ND8PR
  • NOTE: Clinical response was defined by Response Evaluation Criteria in Solid Tumors. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease. Cases 1, 2, 7, 9, and 12 had no pretreatment plasma samples. NA, not applicable. All cases, except case 9, had gefitinib treatment. Case 9 had erlotinib treatment. Del19 denotes deletion in EGFR exon 19. ND, not detected. NA, not available. All L858R mutation are 2573T>G. All numerical figures are correct to two significant figures.

  • * Samples were collected during treatment, except for case 9. Erlotinib treatment was stopped in case 9, 4 wk before plasma collection.